関連する実験動画
Updated: Feb 13, 2026

09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
19.0K
次世代のタンパク質・コロル・バイオアセンブリは,転移性三重陰性乳がんモデルにおいて,効果的な腫瘍殺菌治療を提供している
bioRxiv : the preprint server for biology
|February 12, 2026
まとめ
新しいタンパク質ベースのナノ粒子は,HER3陽性がんを標的にし,トリプルネガティブ乳がんモデルにおける腫瘍と転移を最小限の毒性で効果的に減少させ,有望な新しい治療法を提供します.
科学分野:
- バイオテクノロジー バイオテクノロジー
- ナノメディシンは,ナノ医療です.
- 腫瘍学 腫瘍学
背景:
- 腫瘍を標的とするタンパク質と組み合わせた化学療法薬は,耐性がんの治療に有望であることが示されています.
- 生物化学的特徴は,そのような薬剤の治療的展開に不可欠です.
研究 の 目的:
- HER3を標的とするカプソメア (HPK2.0) を開発・最適化して,安定で強力な抗がん組成を作り出す.
- 三重陰性乳がん (TNBC) モデルにおけるHPK2.0-コロールナノ複合体の有効性と安全性を評価する.
主な方法:
- HPK2.0カプソメアは,細胞毒性コーロールとの組み立てのために開発され,最適化されました.
- 静電中和と形状の互補性によるナノコンプレックス形成.
- TNBCの細胞系とオーソトピック転移性TNBCのマウスモデルを用いたin vitroおよびin vivo研究.
主要な成果:
- HPK2.0-コロールナノコンプレックスは,持続的な血清安定性,HER3依存性腫瘍の侵入,および効率的な内分体脱出を示した.
- TNBC細胞で観察された強力で選択的な細胞毒性.
- 腫瘍の有意な回帰 (67-83%),肺転移の抑制,および生存率の改善 (約2倍) が微小な毒性で体内で行われました.
結論:
- HPK2.0のタンパク質・コロル・プラットフォームは,転移性HER3陽性TNBCを治療するための臨床的にスケーラブルな戦略を提供します.
- 腫瘍の特異性と治療効力の統合が達成されました.
- この次世代プラットフォームは,HER3陽性がんの治療抵抗を克服する可能性を示している.
さらに関連する動画
05:05Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
Published on: November 29, 2018
11.7K
09:44Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior
Published on: June 13, 2016
8.9K
関連する概念動画
Protein Complex Assembly
16.9K
Proteins can form homomeric complexes with another unit of the same protein or heteromeric complexes with different types. Most protein complexes self-assemble spontaneously via ordered pathways, while some proteins need assembly factors that guide their proper assembly. Despite the crowded intracellular environment, proteins usually interact with their correct partners and form functional complexes.
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Many viruses self-assemble into a fully functional unit using the infected host cell to...
16.9K
Protein Complex Assembly
2.6K
2.6K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Gram-negative Bacterial Protein Secretion Systems
1.0K
Gram-negative bacteria utilize sophisticated protein secretion systems to transport proteins across their double-membrane envelope into the extracellular environment or host cells. Based on their mechanism of action, these systems are classified into one-step and two-step pathways.One-Step Secretion Systems (Types I, III, IV, and VI)One-step secretion systems bypass the periplasm entirely, forming a continuous channel that spans both the inner and outer membranes:Type I Secretion System (T1SS):...
1.0K
Negative Regulator Molecules
38.6K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.6K
Scalar and Vector Triple Products
4.5K
Two vectors can be multiplied using a scalar product or a vector product. The resultant of a scalar product is scalar, while with vector products, the resultant is a vector. These rules of the scalar or vector product between two vectors can be applied to multiple vectors to obtain meaningful combinations. The scalar triple product is the dot product of a vector with the cross product of two vectors.
The scalar triple product is the dot product of a vector with the cross product of two vectors....
The scalar triple product is the dot product of a vector with the cross product of two vectors....
4.5K